Arrowhead Pharmaceuticals Inc. (ARWR)

39.79
0.81 2.10
NASDAQ : Health Technology
Prev Close 38.98
Open 38.89
Day Low/High 38.00 / 40.09
52 Wk Low/High 10.41 / 39.25
Volume 1.20M
Avg Volume 1.36M
Exchange NASDAQ
Shares Outstanding 95.30M
Market Cap 3.43B
EPS -0.70
P/E Ratio 78.15
Div & Yield N.A. (N.A)
Arrowhead Research To Report Fiscal 2011 Second Quarter Financial Results And Host Conference Call On Thursday, May 12, 2011

Arrowhead Research To Report Fiscal 2011 Second Quarter Financial Results And Host Conference Call On Thursday, May 12, 2011

Arrowhead Research Corporation (NASDAQ:ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that it will report its financial results for the fiscal...

Arrowhead Research To Present At The 2011 MDB Capital Group Bright Lights Conference On May 10

Arrowhead Research To Present At The 2011 MDB Capital Group Bright Lights Conference On May 10

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr.

Arrowhead Research Announces RNAi Leader John J. Rossi, Ph.D. To Join Calando Scientific Advisory Board

Arrowhead Research Announces RNAi Leader John J. Rossi, Ph.D. To Join Calando Scientific Advisory Board

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that John J.

Arrowhead Research Increases Ownership In Ablaris To 64%

Arrowhead Research Increases Ownership In Ablaris To 64%

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that majority-owned subsidiary Ablaris Therapeutics, Inc.

Arrowhead Research To Present At The Roth Capital Partners 23rd Annual OC Growth Stock Conference On March 16

Arrowhead Research To Present At The Roth Capital Partners 23rd Annual OC Growth Stock Conference On March 16

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr.

Arrowhead Reports Fiscal 2011 First Quarter Financial Results

Arrowhead Reports Fiscal 2011 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 first quarter...

Arrowhead Research To Present At The 13th Annual BIO CEO & Investor Conference

Arrowhead Research To Present At The 13th Annual BIO CEO & Investor Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company, today announced that Dr.

Arrowhead Research To Report Fiscal 2011 First Quarter Financial Results And Host Conference Call On Thursday, February 10, 2011

Arrowhead Research To Report Fiscal 2011 First Quarter Financial Results And Host Conference Call On Thursday, February 10, 2011

Arrowhead Research Corporation (NASDAQ: ARWR), a focused nanomedicine holding company, today announced that it will report its financial results for the fiscal 2011 first quarter ended December 31, 2010, on Thursday,...

Arrowhead Subsidiary Unidym, Inc. Acquired By Wisepower Co., Ltd. For Up To $140 Million Earn-Out Plus $5 Million Upfront

Arrowhead Subsidiary Unidym, Inc. Acquired By Wisepower Co., Ltd. For Up To $140 Million Earn-Out Plus $5 Million Upfront

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its Unidym, Inc.

Arrowhead Increases Investment In RNAi Subsidiary Calando Pharmaceuticals

Arrowhead Increases Investment In RNAi Subsidiary Calando Pharmaceuticals

Arrowhead Research Corporation (NASDAQ: ARWR) (“the Company”) today announced that it has invested $1 million in its majority owned subsidiary, Calando Pharmaceuticals, and converted approximately $8M of ...

8 Penny Stocks Get Delisting Warning

8 Penny Stocks Get Delisting Warning

Another round of small-cap companies are on watch by the Nasdaq and NYSE to be delisted in six months.

Arrowhead Research CEO Discusses F4Q2010 Results – Earnings Call Transcript

Arrowhead Research CEO Discusses F4Q2010 Results – Earnings Call Transcript

Arrowhead Research CEO Discusses F4Q2010 Results â¿¿ Earnings Call Transcript

Arrowhead Reports Fiscal 2010 Fourth Quarter And Year-End Financial Results

Arrowhead Reports Fiscal 2010 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2010 fourth quarter and year ended September 30, 2010.

Arrowhead Starts New Subsidiary, Ablaris Therapeutics, To Commercialize Anti-Obesity Technology

Arrowhead Starts New Subsidiary, Ablaris Therapeutics, To Commercialize Anti-Obesity Technology

Arrowhead Research Corporation (NASDAQ: ARWR) (“Arrowhead” or the “Company”) today announced that it has executed an exclusive world-wide license on technology developed by Drs.

Arrowhead Research To Report Fiscal 2010 Fourth Quarter And Year-End Financial Results And Host Conference Call On Wednesday, December 22, 2010

Arrowhead Research To Report Fiscal 2010 Fourth Quarter And Year-End Financial Results And Host Conference Call On Wednesday, December 22, 2010

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2010 fourth quarter and year ended September 30, 2010, on Wednesday, December 22, 2010 at 4:30 p.

Arrowhead CEO Provides Perspective On $4.5 Million Alliance Between Subsidiary Unidym And Samsung Electronics

Arrowhead CEO Provides Perspective On $4.5 Million Alliance Between Subsidiary Unidym And Samsung Electronics

Arrowhead Research Corporation’s (NASDAQ: ARWR) (“the Company”) President and Chief Executive Officer today issued the following open letter to the Company’s shareholders: Dear...

Unidym Announces Alliance With Samsung Electronics

Unidym Announces Alliance With Samsung Electronics

Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that it has completed IP cooperation and license agreements with Samsung Electronics Co.

BBC Broadcasts Interview With Dr. Samuel Stupp, Founder Of Arrowhead Portfolio Company, Nanotope, Inc.

BBC Broadcasts Interview With Dr. Samuel Stupp, Founder Of Arrowhead Portfolio Company, Nanotope, Inc.

An interview with Dr. Sam Stupp, founder and scientific advisor to Nanotope, Inc.

Arrowhead Strengthens Board Of Directors With The Appointment Of Dr. Douglass Given

Arrowhead Strengthens Board Of Directors With The Appointment Of Dr. Douglass Given

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Douglass Given MD, PhD, MBA, has joined the Company’s Board of Directors, expanding Arrowhead’s Board to a total of six directors.

Arrowhead Portfolio Companies, Calando Pharmaceuticals, Inc. And Nanotope, Inc., Awarded Federal Grants To Advance Therapeutics

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its portfolio companies, Calando Pharmaceuticals, Inc.

Arrowhead To Present At Oppenheimer 21st Annual Healthcare Conference

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr.

Arrowhead Portfolio Company, Nanotope, Inc. Enters Agreement With Smith & Nephew For The License And Development Of Cartilage Regeneration Technology

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its portfolio company, Nanotope, Inc.

Arrowhead CEO Provides Update On Company Strategy And Milestone Achievements

Arrowhead Research Corporation’s (NASDAQ: ARWR) (“the Company”) President and Chief Executive Officer today issued the following open letter to the Company’s shareholders: Dear...

Arrowhead To Present At 9th Annual Bio Investor Forum

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that Dr.

Arrowhead Increases Ownership In RNAi Subsidiary Calando Pharmaceuticals, Inc.

Arrowhead Research Corporation (NASDAQ:ARWR) (“the Company”) today announced that it has increased its ownership of majority owned subsidiary Calando Pharmaceuticals through the exchange of Calando Series...

Arrowhead To Present At Rodman & Renshaw Annual Global Investment Conference

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr.

Arrowhead Research Appoints Dr. Mauro Ferrari To Its Board Of Directors

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr.

Arrowhead Research Corp. F3Q10 (Qtr End 06/30/10) Earnings Call Transcript

Arrowhead Research Corp. F3Q10 (Qtr End 06/30/10) Earnings Call Transcript

Arrowhead Reports Fiscal 2010 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ:ARWR) today announced financial results for its fiscal 2010 third quarter ended June 30, 2010.

Arrowhead Options Obesity-Fighting Technology From MD Anderson Cancer Center

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of...

TheStreet Quant Rating: C (Hold)